Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Nova Stream

 

NephroPlus acquires DaVita India

India's largest dialysis operator NephroPlus has further consolidated the national market with the acquisition of global dialysis giant DaVita's Indian operations. We talk to NephroPlus CEO Vikram Vuppala about the deal and the Indian dialysis market.

KKR ‘nearing deal to buy Acadia’

The American press is reporting that US-based private equity giant KKR is ‘nearing a deal’ to buy addiction treatment specialists Acadia Healthcare. The purchase would bring one of America's largest PE giants into the UK healthcare industry for the first time. How are KKR's international healthcare investments fairing?

Is IHH pulling out of Europe to focus on Asia?

Recent developments point to pan-Asian hospital group IHH scaling down Acibadem, its Turkey-based subsidiary. What does this mean for its interest in Europe? We talk to well-placed sources about what a falling lira, shareholder restructuring, asset sales in Bulgaria and Macedonia, and IHH’s acquisition of Indian chain Fortis might mean.

Spanish hospital group continues expansion in South America

Grupo Hospiten, a Spain-based hospital group with a presence in South America, has opened a new hospital in Mexico. We speak to the company's corporate medical director about its business, its market and its strategy in the region.

Ada opens up markets with new languages

German telehealth company Ada claims that introducing new languages on its AI-powered "symptom checker" app will eventually open the market up to an additional 102 million people.

Quest Diagnostics changes strategy in emerging markets

Last week Healthcare Nova reported that US-based lab company Quest Diagnostics had sold its Indian medical diagnostics arm to Strand Life Sciences. We also reported that Quest has set up an international alliance of lab companies based in Brazil, Saudi Arabia, Korea, Hong Kong and Australia. Are the two moves connected? We speak to Quest's MD of global markets, Mark Machulcz to find out more about the group's change of strategy.

Find Us